SLRX•globenewswire•
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”
Summary
Company has pro forma cash of approximately $14 million following recent public offering Company has pro forma cash of approximately $14 million following recent public offering
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 19, 2025 by globenewswire